Company intelligence / Profile preview

Berg Haus

Boston, Massachusetts, USAberghaus.ee ↗

Ownership: Private
Employees: ~225
Development stage: Other

Overview

BERG developed a proprietary AI-driven drug discovery platform integrating multiomics data to identify disease mechanisms. Its lead program BPM 31510 reached Phase 2 trials for skin cancer. The company partnered with major academic centers and pharma companies to advance its pipeline before being acquired by BPGbio in 2023.

Therapeutic areas: Oncology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

AstraZenecaHarvard UniversityMD Anderson Cancer CenterCornell University Medical CenterPalo Alto Medical Foundation

Beyond the preview

Go deeper on Berg Haus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Berg Haus.

Explore the full profile